550 Tylenol Autism Lawsuits Revived: What Every Parent Needs to Know After the 2026 Appeals Court Bombshell

Breaking: Second Circuit Revives Hundreds of Prenatal Tylenol Autism Lawsuits

In a landmark ruling that has sent shockwaves through the pharmaceutical and legal industries, the U.S. Court of Appeals for the Second Circuit on July 13, 2026 vacated the dismissals of approximately 550 lawsuits alleging that prenatal use of Tylenol (acetaminophen) caused children to develop Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) [1]. The ruling sends those cases back to the U.S. District Court for the Southern District of New York for further proceedings — a major victory for thousands of families who have spent years fighting for accountability [1].

The appeals court found that the lower court had "overstepped its gatekeeping function" when it excluded the testimony of three key plaintiffs' expert witnesses, effectively gutting the lawsuits before they could go to trial [1] [21]. The ruling does not resolve the question of whether acetaminophen causes ASD or ADHD — that fight is just beginning again — but it ensures that hundreds of families will get their day in court [1].

A Litigation Timeline: From MDL Consolidation to Appellate Reversal

The mass tort litigation consolidated in federal court under In Re: Acetaminophen – ASD/ADHD MDL No. 3043, established in October 2022 in the Southern District of New York [1]. What started with a handful of lawsuits rapidly grew: there were 107 pending cases by March 2023, 265 by September 2023, and 441 by November 2023 [4] [10]. At its peak, the federal MDL housed more than 500 cases before the district court's rulings halted the litigation in its tracks [1].

Presiding over the MDL was U.S. District Judge Denise L. Cote, whose rulings proved decisive — and controversial. In December 2023, Judge Cote issued her first Daubert opinion, excluding five of the plaintiffs' expert witnesses on general causation, finding their methodologies unreliable [1] [21]. A second opinion in July 2024 excluded a sixth expert, Dr. Roberta Ness [1]. With their experts eliminated, the plaintiffs could not establish causation, and in August 2024, summary judgment was granted to the defendants — effectively ending the federal cases [1].

Plaintiffs appealed under Case No. 24-2594 in the Second Circuit, with the lead case captioned Rutledge v. Walgreen [1]. The appellate panel's July 13, 2026 ruling reversed the exclusion of three of the plaintiffs' experts — Dr. Andrea Baccarelli, Dr. Eric Hollander, and Columbia University toxicologist Brandon Pearson — while affirming the exclusion of two others (Dr. Cabrera and Dr. Louie) and declining to rule on a sixth expert in a companion lawsuit [1] [21].

What the Appeals Court Actually Decided

The Second Circuit's ruling is both a victory and a measured one. The appeals panel made clear it was not deciding whether acetaminophen actually causes ASD or ADHD [1]. Rather, it found that Judge Cote applied too stringent a standard when she excluded the three reinstated experts, ruling that those experts "used standard methodologies" and offered "acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree" [1] [21].

This distinction matters enormously for families following the litigation. The cases have been remanded — sent back — to the district court, where the battle over expert testimony and general causation will need to be re-litigated [1]. Only after that threshold question is resolved will individual trials, or potentially a global settlement, become possible [15].

Kenvue Brands LLC, the Tylenol maker spun off from Johnson & Johnson in 2023, responded swiftly, calling the ruling "procedural" and asserting it "did not address the scientific merits of the case." [24] The company stated it intends to continue defending these cases vigorously and is exploring all options regarding the decision [24].

Who Is Suing — and Who They Are Suing

The plaintiffs are families of children who were diagnosed with ASD and/or ADHD after their mothers used Tylenol during pregnancy [1] [4]. The defendants include major manufacturers and retailers, including Kenvue Brands LLC (the maker of Tylenol) and Johnson & Johnson, as well as retailers like Walgreens and Walmart who sold store-brand acetaminophen products [1] [4].

Leading the charge for plaintiffs is Keller Postman, one of the nation's most prominent mass tort litigation firms. Ashley Keller, a founding partner at Keller Postman, has been a key figure in the litigation [5] [16]. Keller Postman also serves as outside counsel for the State of Texas in a related state-level lawsuit [5]. Additional plaintiffs' firms include Sokolove Law, Dolman Law Group, and Saiontz & Kirk, among others [4] [20]. Kirkland & Ellis has been identified among defense counsel [1].

New plaintiffs may still join the MDL using a streamlined "Short Form Complaint" process [10]. Legal experts suggest that tens of thousands of additional victims could potentially file lawsuits as the litigation moves forward [10].

Texas Takes Action: The State-Level Battle

The federal MDL is not the only legal front in this war. On October 28, 2025, Texas Attorney General Ken Paxton filed a lawsuit against Johnson & Johnson and Kenvue, alleging they deceptively marketed Tylenol to pregnant mothers while allegedly knowing of increased risks of autism and other disorders from early acetaminophen exposure [25]. The Texas AG's lawsuit alleges the companies "willfully ignored and attempted to silence the science" on prenatal acetaminophen risks [25].

This state-level action underscores the breadth of the legal and regulatory battle now facing Kenvue and Johnson & Johnson — one that extends far beyond the courtrooms of New York [25]. State courts across the country also continue to see acetaminophen-related cases filed independently of the federal MDL [20].

The Science: What Studies Say (and What They Don't)

The scientific debate over prenatal acetaminophen exposure and neurodevelopmental disorders is complex, contested, and critical to the outcome of these lawsuits. Here is a comprehensive look at what the research shows.

Studies Suggesting a Link

A landmark 2019 Johns Hopkins University study found that prenatal acetaminophen exposure may increase a child's risk for ADHD or ASD, with children who had the highest levels of acetaminophen in their umbilical cord blood being nearly three times more likely to be diagnosed with ASD or ADHD [6] [29]. A separate 2019 National Institutes of Health (NIH) study similarly suggested a link between in-utero acetaminophen exposure and higher risks of ADHD and/or autism [6].

A 2020 study published in JAMA Psychiatry found a statistically significant correlation between in-utero acetaminophen exposure and increased risks of childhood ADHD and ASD in a cohort of 996 mother-infant pairs [10] [30]. A 2018 meta-analysis involving data from more than 132,000 mother-child pairs indicated that prolonged exposure could increase the risk of autism by approximately 20% and ADHD by about 30% [10] [12].

Most recently, a meta-analysis published on August 14, 2025 in BMC Environmental Health, conducted by researchers at the Icahn School of Medicine at Mount Sinai and analyzing 46 previous studies using the Navigation Guide methodology, found evidence supporting an association between prenatal acetaminophen exposure and increased incidence of neurodevelopmental disorders [27]. The senior author was Dr. Andrea Baccarelli, Dean of the Harvard T.H. Chan School of Public Health — who is also one of the three reinstated expert witnesses in the federal MDL [27] [30].

Studies Finding No Causal Link

The defense has powerful scientific ammunition as well. A large 2024 Swedish study published in JAMA, which analyzed data from almost 2.5 million children, found no causal link between prenatal acetaminophen use and autism, ADHD, or intellectual disability when comparing sibling pairs — suggesting that genetics or parental characteristics, not acetaminophen itself, may account for observed associations [33]. Multiple studies published in 2026, including a 20-year study from Hong Kong and a large Danish study, have similarly reported no evidence of a link between Tylenol during pregnancy and increased risks of autism or ADHD [33].

The World Health Organization (WHO) has stated that there is no conclusive scientific evidence connecting prenatal acetaminophen (paracetamol) use with autism [3]. This scientific divergence is precisely why the Second Circuit found it premature to exclude the plaintiffs' expert witnesses — and why the causation debate will continue to be fought in courtrooms and medical journals alike [1] [21].

The FDA Steps In: A Historic Label Change Process

On September 22, 2025, the U.S. Food and Drug Administration (FDA) took a significant step by initiating the process for a label change for acetaminophen products — including Tylenol — to reflect evidence suggesting a possible association between prenatal use and increased risks of neurological conditions like autism and ADHD [28] [34]. The FDA also issued a letter alerting physicians nationwide to the potential risks [28].

Importantly, the FDA has emphasized that while an association has been described in some studies, a causal relationship has not been established, and contrary studies exist [28] [34]. The agency also notes that acetaminophen remains the only over-the-counter drug approved for use in treating fevers during pregnancy, and that untreated high fevers can themselves pose serious risks to fetal development [28] [34]. The FDA's advisory guidance suggests minimizing acetaminophen use during pregnancy for routine, low-grade fevers, while acknowledging that it remains the safest OTC option compared to aspirin or ibuprofen [28].

The FDA's action — initiating a label change process — is a remarkable development that plaintiffs' attorneys are expected to cite as evidence that the risks were knowable and that warnings were inadequate for years [28] [34].

The Three Reinstated Experts: Who They Are and Why They Matter

The fate of 550 lawsuits hinged in large part on the credibility and admissibility of expert testimony. The three experts whose reinstatement the Second Circuit ordered are among the most distinguished scientists in their fields [1].

Dr. Andrea Baccarelli is the Dean of the Harvard T.H. Chan School of Public Health, one of the most prestigious public health institutions in the world [27] [30]. He served as senior author of the 2025 Mount Sinai meta-analysis that found evidence supporting a link between prenatal acetaminophen and neurodevelopmental disorders [27]. His reinstatement is perhaps the most significant single development in the litigation.

Dr. Eric Hollander is a psychiatrist and director of the autism and obsessive-compulsive spectrum program at New York City's Albert Einstein College of Medicine, widely regarded as a leading authority on autism [1]. Brandon Pearson is a toxicologist at Columbia University whose work focuses on environmental exposures and neurodevelopmental outcomes [1].

The Second Circuit ruled that Judge Cote erred in excluding these three experts, finding that their methodologies were sound and that their opinions fell within the range of "acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree" [1] [21]. With their testimony reinstated, the plaintiffs now have a credible path to establishing general causation in the district court [1].

How Many People Could Be Affected?

The potential scope of this litigation is staggering. Studies suggest that over 65% of women in the United States use acetaminophen during pregnancy — making it one of the most widely used medications during gestation [10] [12]. Meanwhile, the CDC reported in April 2023 that approximately 1 in every 36 children in the U.S. is diagnosed with autism, with ASD being 3.8 times more prevalent among boys than girls [32].

The lawsuits focus primarily on children whose mothers used acetaminophen during the second and third trimesters of pregnancy, with some research suggesting the risk may be most pronounced with chronic, long-term use throughout the pregnancy [10] [12] [29]. Legal firms monitoring the litigation anticipate that tens of thousands of additional victims and families could potentially file lawsuits as awareness of the litigation grows [10].

What Are These Lawsuits Worth? Projected Settlements and Verdicts

As of July 2026, no settlements have been announced in the federal MDL, and no jury verdicts have been returned — the federal cases were stalled by the exclusion of expert testimony and subsequent dismissal before any trials could occur [15] [20].

However, legal experts and mass tort analysts project that Tylenol settlement amounts could potentially reach $500,000 or more in individual cases, with jury verdicts potentially reaching into the millions for the most serious cases [15]. Factors that will influence individual settlement values include:

• The severity of the child's ASD or ADHD diagnosis [15]

• Medical expenses and ongoing therapy costs [15]

• Lost future wages and earning capacity [15]

• Pain and suffering of the child and family [15]

• Documentation of acetaminophen use during pregnancy [10]

• Duration and frequency of acetaminophen exposure [12]

These projections remain speculative until general causation is established in the district court and individual cases begin moving toward trial or settlement negotiations [1] [15].

What Kenvue and Johnson & Johnson Are Saying

Kenvue Brands LLC has been consistent and firm in its public position. The company maintains that "credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder (ADHD)" [24]. Following the Second Circuit ruling, Kenvue emphasized that the decision was procedural in nature and did not address the scientific merits of the underlying claims [24]. The company stated it intends to continue vigorously defending the cases and is exploring all available legal options [24].

However, the Texas Attorney General's lawsuit paints a starkly different picture, alleging that Johnson & Johnson and Kenvue "willfully ignored and attempted to silence the science" on prenatal acetaminophen risks [25] — an allegation the companies vigorously deny. If internal company documents are ultimately produced in discovery, they could prove to be among the most consequential evidence in the entire litigation [25].

What Comes Next: The Road Ahead for Families

With the Second Circuit's ruling in hand, the approximately 550 revived cases will return to Judge Cote's courtroom in the Southern District of New York for further proceedings [1]. The district court must now conduct a new, more deferential review of the three reinstated expert witnesses consistent with the Second Circuit's guidance [1] [21]. If those experts survive the revised gatekeeping analysis, the litigation could proceed toward a bellwether trial structure — where a handful of representative cases go to trial first, setting the stage for broader settlement negotiations [15].

State court lawsuits will continue to proceed on their own timelines, independent of the federal MDL [20]. The Texas AG lawsuit, with the backing of the state's legal resources and Keller Postman as outside counsel, represents a significant additional pressure point on the defendants [25] [5].

New plaintiffs may still join the federal MDL using a streamlined Short Form Complaint process, though specific new filing deadlines following the appeals court decision will be set by the district court upon remand [10]. Families who believe they may qualify are strongly encouraged to consult with a qualified mass tort attorney as soon as possible, as statutes of limitations vary by state and delay can compromise a claim [4] [20].

Do You Qualify? Who Can File a Tylenol Autism Lawsuit

You may have a potential legal claim if all of the following generally apply to your situation [4] [10]:

• You used Tylenol or another acetaminophen-containing product during your pregnancy

• Your child has been diagnosed with Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD)

• The acetaminophen use occurred during the second and/or third trimester of pregnancy

• Your child's diagnosis was made within the applicable statute of limitations period in your state

Families are urged not to wait. The Second Circuit ruling has reopened a window that was previously closed, but legal deadlines are real and unforgiving [10] [20]. Consulting with an experienced mass tort attorney — who can evaluate the specific facts of your case at no cost — is the critical first step [4].

The Bottom Line

The July 13, 2026 Second Circuit ruling is one of the most significant developments in pharmaceutical mass tort litigation in years [1]. It resurrected hundreds of lawsuits that had been dismissed, restored the voices of three highly credentialed scientific experts, and signaled that the legal and scientific battles over prenatal Tylenol use are far from over [1] [21].

For the tens of thousands of families raising children with ASD or ADHD — conditions that can require a lifetime of costly therapy, specialized education, and support — the stakes could not be higher [32] [15]. The litigation will continue to evolve rapidly, and staying informed is essential.

This article is for informational purposes only and does not constitute legal advice. If you believe you or your child may have been harmed by prenatal acetaminophen exposure, please consult a qualified attorney.